表紙
市場調査レポート

血管性認知症:世界の治験レビュー

Vascular Dementias Global Clinical Trials Review, H1, 2016

発行 GlobalData 商品コード 310348
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
血管性認知症:世界の治験レビュー Vascular Dementias Global Clinical Trials Review, H1, 2016
出版日: 2016年05月19日 ページ情報: 英文 60 Pages
概要

当レポートでは、血管性認知症に関する臨床研究の最新動向について分析し、疾患治療法の概要や、治験における主要国、G7諸国およびE7(新興7カ国)における治験数および被験者採用の状況、フェーズ(相)段階別の進行状況、有望なスポンサー、各企業研究機関での研究の進行状況、有望な薬剤の比較といった情報をまとめてお届けします。

目次

イントロダクション

  • 血管性認知症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東およびアフリカにおける治験件数

G7諸国での治験件数:中枢神経系の治験件数に対する血管性認知症の治験件数比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国(新興7カ国)での治験件数:中枢神経系の治験件数に対する血管性認知症の治験件数比率

E7諸国(新興7カ国)での治験件数:フェーズ(相)別

E7諸国(新興7カ国)での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ(相)別

進捗状況別の治験件数

エンドポイント達成状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別治験件数

有望なスポンサー

有望な薬剤

最新の治験情報

治験のプロファイル

  • 代表的な企業の治験概要
    • Pfizer Inc.
    • Johnson & Johnson
    • Novartis AG
    • Janssen-Cilag A.G.
    • Golgi Pharmaceuticals Ltd
    • EVER Neuro Pharma GmbH
    • エーザイ
    • Dr. Willmar Schwabe Pharmaceuticals
    • Diaxonhit S.A.
  • 代表的な大学・研究所における治験の概要
    • University of Pennsylvania
    • Ministry of Education, Culture, Sports, Science and Technology
    • Radboud University
    • University of Pittsburgh
    • Cardiff University
    • University of Western Sydney
    • Chang Gung Memorial Foundation
    • VU University Medical Center
    • Samsung Medical Center
    • The Sheba Medical Center

5つの代表的な治験のプロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3410CTIDB

GlobalData's clinical trial report, "Vascular Dementias Global Clinical Trials Review, H1, 2016" provides an overview of Vascular Dementias clinical trials scenario. This report provides top line data relating to the clinical trials on Vascular Dementias. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Clinical Trials by G7 Countries: Proportion of Vascular Dementias to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Vascular Dementias to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Vascular Dementias Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Vascular Dementias Therapeutics, Global, Clinical Trials by Region, 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Proportion of Vascular Dementias to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
  • Vascular Dementias Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Vascular Dementias Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Vascular Dementias to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
  • Vascular Dementias Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Vascular Dementias Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Vascular Dementias Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Vascular Dementias Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Vascular Dementias Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Proportion of Vascular Dementias to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
  • Vascular Dementias Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Vascular Dementias Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Vascular Dementias to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
  • Vascular Dementias Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Vascular Dementias Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Vascular Dementias Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Vascular Dementias Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Vascular Dementias Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top